Answers are grounded in this paper and cite their sources.
Case report highlights successful management of cutaneous mucormycosis in a renal transplant patient, suggesting isavuconazole as an effective alternative.
A 52 years old male cadaveric renal transplant recipient developed cutaneous mucormycosis, presenting with febrile toxicity and a rapidly growing black lesion. Diagnosis was confirmed by biopsy and treatment began with liposomal amphotericin B. Owing to the high mortality associated with mucormycosis, isavuconazole, a non-nephrotoxic antifungal, was added to Amphotericin B. The patient underwent surgical debridement and his condition subsequently stabilized, accompanied by improved renal function. He was discharged on a combination of isavuconazole and other medications, with good wound healing and a creatinine level of 1.6 mg/dl at one-month follow-up. This case highlights prompt diagnosis and treatment and maintenance with isavuconazole as a viable alternative for mucormycosis in transplant patients with renal impairment.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: